Robotic surgery using Senhance® robotic platform: single center experience with first 100 cases

Robotic surgery using Senhance® robotic platform: single center experience with first 100 cases

Until recently, robotic surgery has been associated only with the da Vinci robotic system. A novel Senhance ® robotic system (TransEnterix Surgical Inc., Morrisville, NC, USA) was introduced almost 5 years ago. Published reports on experience using this robotic platform are very limited. We present...

Full description

Saved in:
Bibliographic Details
Published in:Journal of robotic surgery Vol. 14; no. 2; pp. 371 - 376
Main Authors: Samalavicius, Narimantas Evaldas, Janusonis, Vinsas, Siaulys, Raimondas, Jasėnas, Marius, Deduchovas, Olegas, Venckus, Raimondas, Ezerskiene, Viktorija, Paskeviciute, Renata, Klimaviciute, Geda
Format: Journal Article
Language:English
Published: London Springer London 01-04-2020
Springer Nature B.V
Subjects:
Abdomen
Abdominal surgery
Blood transfusions
Cameras
Cholecystectomy
Colorectal cancer
Colorectal surgery
FDA approval
Feedback
Gynecology
Haptics
Hospitals
Hysterectomy
Laparoscopy
Medical personnel
Medicine
Medicine & Public Health
Minimally Invasive Surgery
Oophorectomy
Original Article
Ovarian cancer
Patients
Quality
Robotic surgery
Surgeons
Surgery
Thoracic surgery
Training
Urology
United States > US
Italy
Robotic surgery
Senhance robotic system
Minimally invasive surgery
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Until recently, robotic surgery has been associated only with the da Vinci robotic system. A novel Senhance ® robotic system (TransEnterix Surgical Inc., Morrisville, NC, USA) was introduced almost 5 years ago. Published reports on experience using this robotic platform are very limited. We present a prospective analysis of the first 100 robotic surgeries in abdominal surgery, gynecology, and urology in Klaipeda University Hospital, Klaipeda, Lithuania. Out of 100 operated patients during the mentioned period, 49 were female and 51 men, age range 27–79 years, on an average 55 years. 39 underwent robotic abdominal surgical procedures, 31—urological, and 30 gynecological surgeries. Duration of surgery varied from 30 min to 6 h and 5 min, on an average 2 h 25 min. Almost half 49 (49%) were operated on for malignant diseases: prostate cancer—27, renal cell carcinoma—1, endometrial cancer—7, ovarian cancer—1, colorectal cancer—13 (7 colon and 6 rectum). In-hospital stay was on an average 4 days, range 1–15 days. There were 3 (3%) conversions: two to laparoscopy (both undergoing robotic radical prostatectomy) and one to open (undergoing total hysterectomy). 6 (6%) complications occurred during 30 postoperative days, 2 demanding surgery. According to the Clavien–Dido classification, they were grade II in 3, grade III a in 1 and grade III b in 2 cases. There was no mortality in this patient population. Our experience with different types of robotic surgeries allows us to state that the Senhance ® robotic system is feasible and safe in general surgery, gynecology, and urology, and wider implementation of this system worldwide is simply a question of time.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1863-2483
1863-2491
DOI:10.1007/s11701-019-01000-6